Fate Therapeutics, Inc.
FATE
$1.00
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.34% | 21.63% | -18.20% | -5.55% | 27.16% |
| Total Depreciation and Amortization | -30.57% | -30.86% | -1.47% | -2.81% | 5.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.13% | -36.52% | 215.95% | 111.41% | -9.82% |
| Change in Net Operating Assets | 101.93% | -975.08% | 54.43% | 210.88% | -127.00% |
| Cash from Operations | 23.89% | -1.38% | 24.12% | 23.13% | -13.38% |
| Capital Expenditure | -2,570.59% | -1,290.70% | 45.86% | 12.39% | 97.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 139.07% | 152.12% | -49.68% | 2.31% | -250.77% |
| Cash from Investing | 136.71% | 146.47% | -49.69% | 2.64% | -260.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.70% | -- | -- | -- | -- |
| Cash from Financing | 4.00% | -- | 1,838.89% | -- | 2,096.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.65% | -88.84% | -121.71% | 70.61% | -1,883.71% |